{"id":11416,"date":"2026-10-19T17:57:20","date_gmt":"2026-10-19T15:57:20","guid":{"rendered":"https:\/\/mumak.me\/?p=11416"},"modified":"2026-10-19T19:46:06","modified_gmt":"2026-10-19T17:46:06","slug":"weekly-market-overview-october-12-october-18-2026","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/portfolio-updates\/weekly-update\/weekly-market-overview-october-12-october-18-2026\/","title":{"rendered":"Weekly Market Overview \u2013 October 12\u2013October 18, 2026"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Strategic realignment: From a semiconductor concentration to a more broadly positioned portfolio<\/h3>

The UMBRELLA Strategy<\/strong> continued its strategic realignment last week. After several weeks with increased exposure to artificial intelligence and semiconductor companies<\/strong>, the latest portfolio adjustments reflect broader diversification across AI, healthcare, and European defense<\/strong>.<\/p>

One of the most important developments was the re-entry of Rheinmetall<\/a><\/strong> following a significant price correction. This means the defense sector is once again represented in the portfolio. At the same time, the position in Alphabet<\/strong><\/a> was significantly expanded, strengthening exposure to AI-driven technologies.<\/p>

The healthcare sector<\/strong> also regained importance. With Eli Lilly<\/a>, Revolution Medicines<\/a>, AbbVie<\/a> and Johnson & Johnson<\/a><\/strong>, it forms a key focus of the strategy.<\/p>

In parallel, exposure to the semiconductor sector was reduced. The position in Dell Technologies<\/strong><\/a> was closed completely.<\/p>

Following these adjustments, the UMBRELLA Strategy comprises ten positions<\/strong>. The equity ratio stands at 99.8%<\/strong>, while the cash component is just 0.2%<\/strong>.<\/p>

Overview of portfolio changes<\/span><\/h4>\t\t\t\t\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/path><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

Increased<\/h2>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Alphabet<\/a><\/p>

Rheinmetall<\/strong><\/a> NEU<\/span><\/code><\/strong><\/span><\/p> \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/path><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

Reduced<\/h2>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Eli Lilly<\/a><\/p>

Intel<\/a><\/p>

Micron Technology<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/circle><\/path><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

Sold<\/h2>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dell Technologies<\/strong><\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Rheinmetall returns: Defense sector back in focus<\/h2>

One of the most significant portfolio decisions of the past week was the reintroduction of Rheinmetall<\/a><\/strong> into the UMBRELLA Strategy.<\/p>

Following a significant price correction, the German defense contractor was readmitted to the portfolio and the position was subsequently increased further. The current weighting is 9.7%<\/strong>.<\/p>

With this decision, the UMBRELLA Strategy once again strengthens its exposure to the European defense industry<\/strong>. The focus is on rising defense spending, the modernization of military equipment, and the long-term expansion of industrial production capacity.<\/p>

The reintroduction of Rheinmetall underscores a selective positioning in the defense sector<\/strong>, without fundamentally changing the strategic focus on technology.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\"Allocation\t<\/a>\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Alphabet becomes a significant AI position<\/h2>

Another focus of last week\u2019s portfolio adjustments was Alphabet<\/strong><\/a>.<\/p>

The existing position was increased further and reached a portfolio weighting of 12.9%<\/strong>, compared with around 4.4% in the previous weekly overview.<\/p>

Together with Palantir Technologies<\/strong><\/a>, Alphabet remains a core component of the UMBRELLA Strategy\u2019s positioning in artificial intelligence<\/strong>.<\/p>

Healthcare sector takes the lead<\/h2>

The healthcare sector<\/strong> now represents the largest sector focus within the UMBRELLA Strategy.<\/p>

Eli Lilly<\/strong><\/a> remains, despite partial profit-taking following positive price development, one of the central portfolio positions with a weighting of 15.9%<\/strong>.<\/p>

Revolution Medicines<\/strong><\/a> remains a significant biotechnology position at 15.7%<\/strong>. The focus is on innovative, targeted therapeutic approaches in oncology.<\/p>

With AbbVie<\/a> (6.5%)<\/strong> and Johnson & Johnson<\/a> (3.2%)<\/strong>, the portfolio also includes established pharmaceutical companies that provide additional diversification and access to medical innovation.<\/p>

Together, these four companies represent around 41.3% of the portfolio<\/strong>.<\/p>

This keeps the UMBRELLA Strategy strongly positioned in the healthcare sector, combining the growth potential of innovative biotechnology companies<\/strong> with the market position of established pharmaceutical groups.<\/p>

Palantir and SpaceX remain core portfolio positions<\/h2>

Palantir Technologies<\/strong><\/a> is currently the largest single position in the UMBRELLA Strategy with a weighting of 16.2%<\/strong>, followed by Eli Lilly<\/strong><\/a> and Revolution Medicines<\/strong><\/a>.<\/p>

Palantir remains a core component of the strategic positioning in AI-supported enterprise software, data analytics, and digital defense infrastructure<\/strong>.<\/p>

SpaceX<\/strong><\/a> is weighted at 14.6%<\/strong> in the portfolio and continues to provide access to advanced technologies and space infrastructure<\/strong>.<\/p>

Exposure to the semiconductor sector reduced<\/h2>

Following the previously increased expansion of semiconductor positions, the UMBRELLA Strategy<\/strong> has reduced its exposure to Intel <\/strong><\/a>and Micron Technology<\/strong><\/a>.<\/p>

Intel<\/strong><\/a> currently holds a weighting of 2.6%<\/strong> in the portfolio, while Micron Technology<\/strong><\/a> accounts for 2.5%<\/strong>.<\/p>

The reductions reflect a more selective positioning in the semiconductor sector<\/strong>. This is driven by increased market volatility, uncertainty regarding capital expenditure on AI infrastructure, and shifting expectations for semiconductor demand.<\/p>

Both companies remain part of the portfolio. This preserves the UMBRELLA Strategy’s exposure to potential future developments in computing infrastructure and memory technologies<\/strong>.<\/p>

Dell Technologies exits the portfolio<\/h2>

The position in Dell Technologies<\/strong><\/a> was sold completely out of the UMBRELLA Strategy.<\/p>

The exit is part of the broader strategic portfolio adjustment<\/strong>, in which capital was specifically reallocated to other focus areas.<\/p>

Although Dell Technologies remains active in enterprise technology and AI infrastructure<\/strong>, the UMBRELLA Strategy is currently focusing more heavily on selected companies in software, healthcare, and defense<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n
\n
\n
\n

Current Positioning<\/h3>\n

UMBRELLA Strategy \u00b7 October 19, 2026<\/p>\n <\/div>\n 10 Positions<\/span>\n <\/div>\n\n

\n
\n Equity Ratio<\/span>\n 99.8%<\/strong>\n
<\/div><\/div>\n <\/div>\n
\n Cash<\/span>\n 0.2%<\/strong>\n
<\/div><\/div>\n <\/div> \n <\/div>\n\n
\n Position \/ Weighting<\/span>\n Performance since inclusion<\/span>\n <\/div>\n\n
\n
\n
\n Palantir Technologies<\/strong>\n
<\/div><\/div>16.2%<\/span><\/div>\n <\/div>\n +9.7%<\/span>\n <\/div>\n\n
\n
\n Eli Lilly<\/strong>\n
<\/div><\/div>15.9%<\/span><\/div>\n <\/div>\n +9.1%<\/span>\n <\/div>\n\n
\n
\n Revolution Medicines<\/strong>\n
<\/div><\/div>15.8%<\/span><\/div>\n <\/div>\n +15.7%<\/span>\n <\/div>\n\n
\n
\n SpaceX<\/strong>\n
<\/div><\/div>14.5%<\/span><\/div>\n <\/div>\n +4.0%<\/span>\n <\/div>\n\n
\n
\n Alphabet A (Google)<\/strong>\n
<\/div><\/div>13.0%<\/span><\/div>\n <\/div>\n \u22121.7%<\/span>\n <\/div>\n\n
\n
\n Rheinmetall<\/strong>\n
<\/div><\/div>9.7%<\/span><\/div>\n <\/div>\n \u22121.0%<\/span>\n <\/div>\n\n
\n
\n Abbvie<\/strong>\n
<\/div><\/div>6.5%<\/span><\/div>\n <\/div>\n +0.3%<\/span>\n <\/div>\n\n
\n
\n Johnson & Johnson<\/strong>\n
<\/div><\/div>3.3%<\/span><\/div>\n <\/div>\n +6.0%<\/span>\n <\/div>\n\n
\n
\n Intel<\/strong>\n
<\/div><\/div>2.5%<\/span><\/div>\n <\/div>\n \u221219.9%<\/span>\n <\/div>\n <\/div>\n \n
\n
\n Micron Technology<\/strong>\n
<\/div><\/div>2.5%<\/span><\/div>\n <\/div>\n \u221212.5%<\/span>\n <\/div>\n <\/div>\n\n

Source: wikifolio.com, UMBRELLA \u00b7 As of: October 19, 2026<\/p>\n<\/div>\n\n